| TECHNOLOGY |
Developing long-acting therapeutic compds based on 2 novel prodt enabling platform technologies for in vivo BIOCONJUGATION. When applied to EXISTING DRUGS, the Co.’s local & systemic technology platforms enable the rapid creation of new drugs with significant enhanced therapeutic properties as compared to the original drug compds. Since the new drugs have biological activities that are patterned after existing drugs, these compds can usually be developed more quickly, less expensively & at a lower risk than most new chemical entities. The Co.’s platform focused on oncology, pain
antiviral, diabetes & thrombosis
|